Characterization of phosphodiesterase 4 in guinea-pig macrophages: Multiple activities, association states and sensitivity to selective inhibitors

British Journal of Pharmacology

Volumn 124, Issue 1, 1998, Pages 129-140

  Kelly, John J ^a   Barnes, Peter J ^a   Giembycz, Mark A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Conformational slates; Cyclic AMP; Guinea pig macrophage; PDE4 isoenzymes; Phosphodiesterase 4

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 5 (4 ACETAMIDOPHENYL) 2(1H) PYRAZINONE; 6 [4 (1,4 DIHYDRO 4 OXO 1 PYRIDYL)PHENYL] 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; CALCIUM CHLORIDE; CALMODULIN; CYCLIC AMP; CYCLIC GMP; ISOPRENALINE; NITRAQUAZONE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; POTASSIUM CHLORIDE; ROLIPRAM; TRITON X 100;

ANIMAL CELL; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL LYSATE; CENTRIFUGATION; CONTROLLED STUDY; DENATURATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GEL FILTRATION; GEL PERMEATION CHROMATOGRAPHY; GUINEA PIG; HEAT TREATMENT; HYDROLYSIS; MACROPHAGE; MALE; MICHAELIS CONSTANT; MOLECULAR WEIGHT; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN CONFORMATION; THERMOSTABILITY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; CYCLIC AMP; ENZYME STABILITY; GUINEA PIGS; HEAT; ISOPROTERENOL; KINETICS; MACROPHAGES; MALE; MOLECULAR WEIGHT; PHOSPHODIESTERASE INHIBITORS;

EID: 0031943533     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701819     Document Type: Article

References (63)

1. VAREZ, R., SETTE, C., YANG, D., EGLEN, R.M., WILHELM, R., SHELTON, E.R. & CONTI, M. (1995). Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol., 48, 616 - 622.
2. BEAVO, J.A., CONTI, M. & HEASLIP, R.J. (1994). Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol., 46, 399 405.
3. BEAVO, J.A. & REIFSNYDER, D.H. (1990). Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends. Pharmacol. Sci., 11, 150 - 155.
4. BOLGER, G., MICHAELI, T., MARTINS, T., ST.JOHN, T., STEINER, B., RODGERS, L., RIGGS, M., WIGLER, M. & FERGUSON, K. (1993). A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol. Cell Biol., 13, 6558 - 6571.
5. BURNS, F., STEVENS, P.A. & PYNE, N.J. (1994). The identification of apparently novel cyclic AMP and cyclic GMP phosphodiesterase activities in guinea-pig tracheal smooth muscle. Br. J. Pharmacol., 113, 3 - 4.
6. CHRISTENSEN, S.B., DEWOLF, W.E., RYAN, M.D. & TORPHY, T.J. (1996). Molecular aspects of inhibitor intercation with PDE4. In Phosphodiesterase Inhibitors, ed. Schudt, C., Dent, G. & Rabe, K.F. pp. 185 207. London: Academic Press.
7. m, cyclic AMP phosphodiesterase: A family of highly related enzymes. In Cyclic Nucleotide Phosphodiesterases: Structure, Function and Drug Action, ed. Beavo, J. & Houslay, M.D. pp. 243 - 266. New York: Wiley
8. DENT, G., GIEMBYCZ, M.A., RABE, K.F. & BARNES, P.J. (1991). Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br. J. Pharmacol., 103, 1339 - 1346.
9. DENT, G., GIEMBYCZ, M.A., EVANS, P.M., RABE, K.F. & BARNES, P.J. (1994a). Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther., 271, 1167 - 1174.
10. DENT, G., GIEMBYCZ, M.A., RABE, K.F., BARNES, P.J. & MAGNUSSEN, H. (1994b). Effect of selective phosphodiesterase inhibitors on human alveolar macrophage cyclic nucleotide hydrolysis and respiratory burst. Br. J. Pharmacol., 111, 74P.
11. DENT, G. & GIEMBYCZ, M.A. (1995). Selective phosphodiesterase inhibitors in the therapy of asthma. Clin. Immunother., 3, 423-437.
12. DENT, G. & GIEMBYCZ, M.A. (1996). Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Thorax., 51, 647 - 649.
13. DINTER, H., ONUFFER, J., FAULDS, D. & PEREZ, H.D. (1997). Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J. Mol. Med., 75, 95-102.
14. DISANTO, M.E. & HEASLIP, R.J. (1993). Identification and stabilization of large molecular weight PDE-IVs from U937 cells. Biochem. Biophys. Res. Commun., 197, 1126 1131.
15. DOWNES, C.P., HAWKINS, P.T. & IRVINE, R.F. (1986). Inositol 1,3,4,5-tetrakisphosphate and not phosphatidylinositol 3,4-bisphosphate is the probable precursor of inositol 1,3,4-trisphosphate in agonist-stimulated parotid gland. Biochem. J., 238, 501 506.
16. ELLIOTT, K. R. & LEONARD, E.J. (1989). Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP. FEBS Lett., 254, 94 - 98.
17. GELS, P., FICHTEL, K. & LUBBERT, H. (1994). Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett., 350, 291-295.
18. EPSTEIN, P.M., STRADA, S.J., SARADA, K. & THOMPSON, W.J. (1982). Catalytic and kinetic properties of purified high-affinity cyclic AMP phosphodiesterase from dog kidney. Arch. Biochem. Biophys., 218, 119-133.
19. FELS, A.O. & COHN, Z.A. (1986). The alveolar macrophage. J. Appl. Physiol., 60, 353-369.
20. FULLER, R.W. (1989). The role of the alveolar macrophage in asthma. Respir. Med., 83, 177-178.
21. GARTNER, I. (1980). Separation of human eosinophils in density gradients of polyvinylpyrrolidone-coated silica gel (Percoll). Immunology., 40, 133-136.
22. GENAIN, C.P., ROBERTS, T., DAVIS, R.L., NGUYEN, M.H., UCCELLI, A., FAULDS, D., LI, Y., HEDGPETH, J. & HAUSER, S.L. (1995). Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U.S.A., 92, 3601-3605.
23. GIEMBYCZ, M.A. (1992). Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem. Pharmacol., 43, 2041 - 2051.
24. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol., 118, 1945-1958.
25. GIEMBYCZ, M.A., DENT, G. & SOUNESS, J.E. (1997). Theophylline and isoenzyme-selective phosphodiesterase inhibitors. In Allergy and Allergic Diseases, ed. Kay, A.B. pp. 531 567. Oxford: Blackwell Scientific.
26. GIEMBYCZ, M.A. & DENT, G. (1992). Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy., 22, 337-344.
27. GIORGI, M., PISCITELLI, D., ROSSI, P & GEREMIA, R. (1992). Purification and characterization of a low-Km 3′:5′-cyclic adenosine phosphodiesterase from post-meiotic male mouse germ cells. Biochim. Biophys. Acta. 1121, 178-182.
28. HOUSLAY, M.D. (1996). N-terminal alternately spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity. Biochem. Soc. Trans., 24, 980-986.
29. HOUSLAY, M.D., SCOTLAND, G., ERDOGAN, S., HLSTON, E., MACKENZIE, S., MCCALLUM, J.F., MCPHEE, I., POOLEY, L., RENA, G., ROSS, A., BEARD, M., PEDER, A., BEGG, F., WILKINSON, I., YARWOOD, S., ACKERMAN, C., HOUSLAY, E.S., HOFFMAN, R., ENGELS, P., SULLIVAN, M & BOLGER, G. (1997). Intracellular targeting, interaction with src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Biochem. Soc. Trans., 25, 374-381.
30. HUGHES, B., OWENS, R., PERRY, M., WARRELLOW, G. & ALLEN, R. (1997). PDE4 inhibitors: the use of molecular cloning in the design and development of novel drugs. Drug Discovery Today, 2, 89 101.
31. STON. E., POOLEY, L., JULIEN, P., SCOTLAND, G., MCPHEE, I., SULLIVAN, M., BOLGER, G & HOUSLAY, M.D. (1996). The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J. Biol. Chem., 271, 31334 31344.
32. 3H]R-(-)-rolipram binding by selective inhibitors. Biochem. J., 318, 425 436.
33. LEE, T.H., POSTON, R., GODARD, P. & BOUSQUET, J. (1991). Macrophages and allergie asthma. Clin. Exp. Allergy., 21, (suppl 1), 22 23.
34. LOUGHNEY, K. & FERGUSSON, K (1996). Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods. In Phosphodiesterase Inhibitors. ed. Schudt, C., Dent, G. & Rabe, K.F. pp. 1 19. London: Academic Press.
35. MANNING, C.D., MCLAUGHLIN, M.M., LIVI, G.P., CIESLINSKI, L.B., TORPHY, T.J. & BARNETTE, M.S. (1996). Prolonged beta adrenoccptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J. Pharmacol. Exp. Ther., 276, 810 818.
36. MULLER, T., ENGELS, P. & FOZARD, J.R. (1996). Subtypes of the type 4 cAMP phosphodiesterases - structure, regulation and selective inhibition. Trends. Pharmacol. Sci., 17, 294 298.
37. NICHOLSON, C.D. & SHAHID, M. (1994). Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulmon. Pharmacol., 7, 1 - 17.
38. 2-stimulatcd cAMP accumulation by lipopolysaccharide in murine peritoneal macrophages. J. Biol. Chem., 266, 10305 - 10312.
39. REEVES, M.L., LEIGH, B.K. & ENGLAND, P.J. (1987). The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors, Biochem. J., 241, 535 541.
40. ROCQUE, W.J., HOLMES, W.D., PATEL, I.R., DOUGHERTY, R.W., ITTOOP, O., OVERTON, L., HOFFMAN, C.R., WISELY, G.B., WILLARD, D.H. & LUTHER, M.A. (1997). Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding. Prof. Exp. Purif., 9, 191 202.
41. SCHADE, F.U. & SCHUDT. C (1993). The specific type III and IV phosphodiesterase inhibitor zardaverinc suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol., 230, 9 14.
42. SCHWARTZ, J.P. & PASSONNEAU, J.V. (1974). Cyclic AMP-mediated induction of the cyclic AMP phosphodiesterase of C-6 glioma cells, Proc. Natl. Acad. Sci. U.S.A., 71, 3844 - 3848
43. SCOTLAND, G. & HOUSLAY, M.D. (1995). Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A:rPDE-IVA1)can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase. Biochem. J., 308, 673 - 681.
44. SEKUT, L., YARNALL, D., STIMPSON, S.A., NOEL, L.S., BATEMAN FITE, R., CLARK, R.L., BRACKEEN, M.F., MENIUS, J.A., JR. & CONNOLLY, K.M. (1995). Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol., 100, 126 132.
45. SETTE, C. & CONTI, M. (1996). Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem., 271, 16526 16534.
46. SHAKUR, Y., PRYDE, J.G. & HOUSLAY, M.D. (1993). Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem. J., 292, 677 686.
47. 1H NMR and identification of the membrane association domain using chimeric constructs. J. Biol. Chem., 271, 16703 16711.
48. SNYDER. D.S., BELLER, D.I. & UNANUE, E.R. (1982). Prostaglandins modulate macrophage Ia expression. Nature., 299, 163 165.
49. SOMMER, N., LOSCHMANN, P.A., NORTHOFF, G.H., WELLER, M., STEINBRECHER, A., STEINBACH, J.P., LICHTENFELS, R., MEYLRMANN, R., RIETHMULLER, A., FONTANA, A., DICHGANS, J. & MARTIN, R. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med., 1, 244 248.
50. SOUNESS, J.E., CARTER, C.M., DIOCEE, B.K., HASSALL, G.A., WOOD, L.J. & TURNER, N.C. (1991). Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem. Pharmacol., 42, 937 945.
51. SOUNESS, J.L. & SCOTT, L.C. (1993). Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem. J., 291, 389 395.
52. STEIN, M. & KESHAV, S. (1992). The versatility of macrophages. Clin. Exp. Allergy., 22, 19 27.
53. STRIETER, R.M., KUNKEL, S.L. & BONE, R.C. (1993). Role of tumor necrosis factor-α in disease states and inflammation. Crit. Care. Med., 21, S447 - S468.
54. SWINNEN, J.V., TSIKALAS, K.E., & CONTI, M. (1991). Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem., 266, 18370 18377.
55. TENOR, H., HATZELMANN, A., KUPFERSCHMIDT, R., STANCIU, L., DJUKANOVIC, R., SCHUDT, C., WENDEL, A., CHURCH, M.K. & SHUTE, J.K. (1995). Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy., 25, 625 633.
56. THOMPSON, W.J. & APPLEMAN, M.M. (1971). Cyclic nucleotide phosphodiesterase and cyclic AMP. Ann. New York Acad. Sci., 185, 36 41.
57. TORPIIY, T.J., DEWOLF, W.E., JR., GREEN, D. W. & LIVI, G.P. (1993a). Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions, Suppl., 43, 51 71.
58. TORPHY, T.J. & UNDEM, B.J. (1991). Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax., 46, 512 523.
59. TORPHY, T.J., UNDEM, B.J., CIESLINSKI, L.B., LUTTMANN, M.A., REEVES, M.L. & HAY, D.W. (1993b). Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther., 265, 1213 1223.
60. 2. Implications for the therapeutic use of β-adrenoceptor agonists. J. Biol. Chem., 270, 23598 23604.
61. TURNER, N.C., WOOD, L.J., BURNS, F.M., GUERLMY, T. & SOUNESS, J.E. (1993). The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages. Br. J. Pharmacol., 108, 876 883.
62. WILSON, M., SULLIVAN, M., BROWN, N. & HOUSLAY, M.D. (1994). Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast. Biochem. J., 304, 407 - 415.
63. WRIGHT, C.D., KUIPERS, P.J., KOBYLARZ SINGER, D., DEVALL, L.J., KLINKEFUS, B.A. & WEISHAAR, R.E. (1990). Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem. Pharmacol., 40, 699 707.